Nektar Therapeutics (NKTR)

Etorro trading 970x250
Nektar Therapeutics (NKTR) Logo

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19.It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California. Address: 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158

Nektar Therapeutics News and around…

Latest news about Nektar Therapeutics (NKTR) common stock and company :

Nektar to Announce Financial Results for the Third Quarter 2021 on Thursday, November 4, 2021, After Close of U.S.-Based Financial Markets
26 Oct, 2021 Yahoo! Finance

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2021 on Thursday, November 4, 2021, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

Hedge Funds Are Buying Nektar Therapeutics (NKTR)
25 Oct, 2021 Yahoo! Finance

The Insider Monkey team has completed processing the quarterly 13F filings for the June quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

Add Up The Pieces: IVOV Could Be Worth $187
25 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard S&P Mid-Cap 400 Value ETF (IVOV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $187.15 per unit.

Noteworthy Thursday Option Activity: NMIH, NKTR, WHR
21 Oct, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in NMI Holdings Inc (NMIH), where a total of 8,529 contracts have traded so far, representing approximately 852,900 underlying shares. That amounts to about 264.8% of NMIH's average daily trading volume over the past month of 322,055 shares..

Tuesday Talk: Gaining Again
19 Oct, 2021 FinancialContent

The market ended last week on an up note and continued to climb yesterday. It seems that September's and early October's wounds have healed. Hard to be sure, but those Israeli Ever Ready Bandage Battle Dressings are out of stock on Amazon.

The Secret To Successful Investing In Biotech
19 Oct, 2021 FinancialContent

Have you ever had a stock jump 30%, 50% or 100% in one day?

12 Health Care Stocks Moving In Monday's After-Market Session
18 Oct, 2021 FinancialContent

Gainers Dermata Therapeutics (NASDAQ:DRMA) stock increased by 28.63% to $5.66 during Monday's after-market session. The market value ...

Interesting NKTR Put And Call Options For December 17th
15 Oct, 2021 FinancialContent

Investors in Nektar Therapeutics (NKTR) saw new options begin trading this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new December 17th contracts and identified one put and one call contract of particular interest.

Noteworthy Tuesday Option Activity: LORL, PLNT, NKTR
05 Oct, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Loral Space & Communications Inc (LORL), where a total of 631 contracts have traded so far, representing approximately 63,100 underlying shares. That amounts to about 71.4% of LORL's average daily trading volume over the past month of 88,430 shares..

Nektar (NKTR) Signs Deals With Pfizer, Merck KGaA for NKTR-255
22 Sep, 2021 Yahoo! Finance

Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.

Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
21 Sep, 2021 FinancialContent

Nektar Therapeutics Inc(NASDAQ: NKTR)has entered into a new oncology clinical collaborationwithMerck ...

Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley Study
21 Sep, 2021 Yahoo! Finance

Nektar Therapeutics (NASDAQ: NKTR) announced it has entered into a new oncology clinical collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to evaluate the maintenance regimen of NKTR-255, Nektar's interleukin-15 (IL-15) receptor agonist, in combination with avelumab, a PD-L1 inhibitor, in patients with locally advanced or metastatic urothelial carcinoma (UC) in the Phase II JAVELIN Bladder Medley study.

Director Of Nektar Therapeutics Trades $544.92 Thousand In Company Stock
13 Sep, 2021 Yahoo! Finance

Robert Chess, Director at Nektar Therapeutics (NASDAQ:NKTR), made a large buy and sell of company shares on September 9, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Robert Chess purchased 18,279 Nektar Therapeutics shares at a price of $13.80 per share for a total of $252,250 on September 9. They then sold their shares on multiple transactions in the open market. They sold at prices ranging from $16.00 to $16.02 to ra

Even after rising 9.3% this past week, Nektar Therapeutics (NASDAQ:NKTR) shareholders are still down 77% over the past three years
02 Sep, 2021 Yahoo! Finance

It's not possible to invest over long periods without making some bad investments. But you want to avoid the really big...

How Bad Are Nektar Therapeutics's Earnings? | Return on Capital Employed
02 Sep, 2021 FinancialContent

Benzinga Pro data, Nektar Therapeutics (NASDAQ:NKTR) reported Q2 sales of $28.33 million. Earnings fell to a loss of $110.20 million, ...

Stocks That Hit 52-Week Lows On Friday
20 Aug, 2021 FinancialContent

On Friday morning, 155 companies achieved new lows for the year. Interesting Points: Marqeta (NASDAQ:MQ) ...

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Monday
16 Aug, 2021 FinancialContent

On Monday morning, 207 companies hit new 52-week lows. Intriguing Points: The largest company in terms of market cap ...

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
13 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Thursday's After-Market Session
12 Aug, 2021 FinancialContent

Gainers Biolase (NASDAQ:BIOL) shares moved upwards by 24.95% to $0.79 during Thursday's after-market session. At the close, ...

Stocks That Hit 52-Week Lows On Thursday
12 Aug, 2021 FinancialContent

During Thursday's morning trading, 83 companies set new 52-week lows. Intriguing Points: KE Holdings ...

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Wednesday
11 Aug, 2021 FinancialContent

On Wednesday morning, 67 companies achieved new lows for the year. Areas of Significance: Grifols ...

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
11 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
10 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Nektar (NKTR) Q2 Earnings and Revenues Top, Pipeline On Track
06 Aug, 2021 Yahoo! Finance

Nektar (NKTR) reports encouraging second-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.

Nektar Therapeutics (NKTR) Q2 2021 Earnings Call Transcript
06 Aug, 2021 FinancialContent

NKTR earnings call for the period ending June 30, 2021.

Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
05 Aug, 2021 Yahoo! Finance

Nektar (NKTR) delivered earnings and revenue surprises of 4.17% and 7.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Nektar Therapeutics (NKTR) is a NASDAQ Common Stock listed in , ,

970x250